A Radical New Interpretation About the Origins of Alzheimer’s Disease

Jul 18, 2022

At Everything Retirement we’ve researched and reported on, frequently and at length, about the origins and management of Alzheimer’s disease.

Put bluntly in a recent article in The Globe and Mail, this brutal condition “is traditionally understood to be caused by the accumulation of abnormal protein in the brain. Get rid of the protein, the thinking goes, and you reduce the harm.”

As simple, and as complicated, as that.

New Research, New Hypothesis

But there’s a Toronto neurologist and medicinal chemist out there who, for the past 20 years, has been exploring an alternative explanation for the condition. His name is Dr. Donald Weaver, and he’s director of the Krembil Brain Institute at Toronto’s University Health Network.

Recently, Dr. Weaver was awarded the silver Oskar Fischer Prize, worth $400,000 USD. The prize, granted through the University of Texas at San Antonio (UTSA), is given to researchers to expand the understanding of Alzheimer’s disease, which has long confounded those seeking a cure.

Dr. Weaver’s hypothesis is that Alzheimer’s is not a neurodegenerative disease, but an autoimmune disease. As The Globe and Mail reports: “His unconventional hypothesis has now won him a major award.”

Quoting Dr. Weaver directly, the newspaper article stated: “What this gives us is external validation and external support and belief that our approach has value, and indeed, may have value leading to alternative therapeutic directions for Alzheimer’s disease.”

It has been approximately 115 years since Alzheimer’s was first documented as a disease, driven by beta amyloid, a protein.

Dr. Weaver takes a contrarian view, suggesting it’s a normal part of the innate immune system in the brain, and plays several roles, including as a messenger and as a bacteria-killer. Anything that produces an immune response, whether it’s an infection, trauma or exposure to noxious substances, triggers cells in the brain to release beta amyloid, he believes.

The problem occurs when beta amyloid mistakes healthy brain cells for bacteria, he was reported as saying. “The end result is that it – oops! – accidentally starts killing brain cells.”

Dr. Weaver’s hypothesis is not definitive, though he believes that the same immune system mechanism may also apply to other diseases, such as Parkinson’s disease or other forms of dementia.

New Ideas Can Often Lead to New Cures

The Globe and Mail story concluded with an observation from Dr. Jenny Hsieh, director of the UTSA Brain Consortium, the body awarding the prize – which included several other winners in hot pursuit of a definitive solution to a problem that has baffled experts for decades.

As Dr. Hsieh observed: “We just need people to be able to work on different ideas, and be inclusive of that, because the bottom line is all of the current approaches to Alzheimer’s disease [are] not working.”

The cure for Alzheimer’s disease is still some time away. But medical science is closing in on it.

Recent Posts

Aviso Weekly Market Pulse: May 20th – May 24th

Market developments Equities: U.S. stocks climbed after data showed consumers tempered their inflation expectations in late May. The S&P 500 had its fifth straight week of gains, the longest bullish streak since February. It topped 5,300 and the Nasdaq 100 rose...

NEI Monthly Market Insights: April 2024

Robust earnings helped mitigate fear of persistent inflation Market sentiment turned bearish in early April for both equity and fixed income markets as sticky U.S. inflation data fuelled market fears that central banks will not ease monetary policy as quickly as...

Aviso Weekly Market Pulse: May 13th – May 17th

Market developments Equities: The stock market has been rallying recently, with the S&P 500 on track for its fourth straight weekly gain. This has been fueled by hopes of Federal Reserve rate cuts following some positive inflation reports, as well as strong...

Aviso Weekly Market Pulse: May 6th – May 10th

Market developments Equities: The S&P 500 closed near 5,225, for its third straight weekly gain, while the Dow rose for an eighth consecutive session. The stock market lost momentum after economic data pointed to a slowing economy amid persistent inflationary...

Aviso Weekly Market Pulse: April 29th – May 3rd

Market developments Equities: The economic data to close out the week was seen as a "Goldilocks" scenario by markets, indicating the economy is cooling enough for the Federal Reserve to likely start cutting interest rates as soon as September. The S&P 500 rose by...

NEI Monthly Market Insights: March 2024

Unstoppable equity market rally on soft landing narrative Resilient economic data throughout the first quarter supported the soft landing narrative and pushed equity markets around the world to new record highs. Global equities posted strong returns with the MSCI ACWI...